Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Beth Israel Deaconess Medical Center
Dartmouth-Hitchcock Medical Center
Melbourne Health
Amgen
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Prelude Therapeutics
Bellicum Pharmaceuticals
Medigene AG
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Bellicum Pharmaceuticals
University of Pennsylvania
Case Comprehensive Cancer Center
Celgene
Celgene
University College, London
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
Benovus Bio, Inc.
Celgene
4SC AG
Cellerant Therapeutics
Indiana University
Indiana University
Rutgers, The State University of New Jersey
University of California, San Francisco
Washington University School of Medicine
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Peter MacCallum Cancer Centre, Australia